Early data from the AURORAS-1 phase I cancer trial suggest that the pan-RAS molecular glue ERAS-0015 produced tumor shrinkage in patients with advanced pancreatic and lung cancers. As a “molecular glue,” ERAS-0015 aims to exploit a synthetic lethality–style dependency by stabilizing or enabling specific protein interactions that drive tumor survival. The report frames the findings as preliminary, but the direction of effect matters for deciding dose expansion cohorts and combination strategies. For drug developers in RAS-driven oncology, the central question now is whether shrinkage translates into clinically meaningful response rates and progression-free durability with manageable toxicity.
Get the Daily Brief